

Forschungsprojekte 2022

Projets de recherche 2022

Unterstützt von: / Soutenus par:

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

Grundlagenforschung / Recherche fondamentale			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Ablasser Andrea , Prof. Global Health Institute Ecole Polytechnique Fédérale de Lausanne (EPFL) 1007 Lausanne	KFS 5514-02-2022 Exploring cGAS checkpoints for cancer immunotherapy	36	374 350.–
AL Nabhani Ziad , Prof. Department for BioMedical Research University of Bern 3008 Bern	KFS 5691-08-2022 Role of inflammatory memory on the colon cancer development	48	374 750.–
Bertoni Francesco , Prof. Dr. med. Faculty of Biomedical Sciences Institute of Oncology Research (IOR) 6500 Bellinzona	KFS 5502-02-2022 G protein-coupled receptors of the olfactory receptors' family provide novel therapeutic opportunities against lymphoma cells	36	341 400.–
Carbone Giuseppina , Dr Laboratory of Prostate Cancer Biology Institute of Oncology Research (IOR) 6500 Bellinzona	KFS 5678-08-2022 Novel epigenetic players in castration- resistant prostate cancer: functional and therapeutic impact	36	368 650.–
Ciriello Giovanni , Dr Computational Biology University of Lausanne 1015 Lausanne	KFS 5615-08-2022 Deciphering the oncogenic effects of mutated chromatin remodelling factors on the chromatin 3D organization	48	316 950.–
Fierz Beat , Prof. ISIC, EPFL SB ISIC LCBM Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS 5640-08-2022 Chemical interference with oncogenic chromatin factors using stapled peptide degraders	48	340 700.–

Geiger Roger , Prof. Dr. Systems Immunology Institute for Research in Biomedicine (IRB) 6500 Bellinzona	KFS 5537-02-2022 Identification of new receptor-ligand signalling axes that suppress T-cells in tumours	36	369 050.–
Greter Melanie , Prof. Experimental Immunology, Myeloid Immunology University of Zurich 8057 Zurich	KFS 5533-02-2022 Deciphering the nature and function of perivascular macrophages in glioma	36	368 250.–
Hall Jonathan , Prof. Institut für Pharmazeutische Wissenschaften ETH Zürich 8093 Zürich	KFS 5504-02-2022 Liver-specific inhibition of Lin28B for treatment of hepatocarcinoma	36	375 000.–
Hediger Matthias , Prof. Inselspital, Department of Nephrology and Hypertension University of Bern 3010 Bern	KFS 5534-02-2022 The role of nutrient transporters in the development of anticancer drug resistance	36	353 100.–
Janscak Pavel , PD Dr. Institut für Molekulare Krebsforschung (Doppelinstitut MeF/MNF) (IMCR) Universität Zürich (UZH) 8057 Zürich	KFS 5484-02-2022 Molecular mechanisms underlying transcription-dependent replication stress induced by RAS oncogenes	24	249 250.–
Karthaus Wouter , Dr med. EPFL SV ISREC Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS 5654-08-2022 Identification of clinically actionable targets for untreatable castration resistant prostate cancer with neuroendocrine differentiation	48	366 950.–
Marti Thomas , PD Dr. Clinic of Thoracic Surgery Inselspital Bern 3010 Bern	KFS 5405-08-2021 Involvement of the lactate dehydrogenase LDHB in lung cancer tumour initiation and therapy resistance	36	362 400.–
Mueller Cristina , PD Dr. Center for Radiopharmaceutical Sciences ETH-PSI-USZ Paul Scherrer Institut (PSI) 5232 Villigen-PSI	KFS 5624-08-2022 Investigation of Auger electron therapy using peptide receptor antagonists that localize at the cellular membrane	48	342 450.–
Pandey Amit V. , PD Dr. Pediatric Endocrinology University of Bern 3010 Bern	KFS 5557-02-2022 Inhibitors of androgen biosynthesis for the treatment of castration-resistant prostate cancer	48	365 000.–
Petrova Tatiana , Prof. Dr Department of Fundamental Oncology Université de Lausanne (UNIL) 1066 Epalinges	KFS 5685-08-2022 Targeting tumour vessels for neogenesis of tertiary lymphoid structures in microsatellite stable colorectal cancer	36	367 300.–

Pillai Ramesh , Prof. Department of Molecular Biology University of Geneva 1211 Geneva	KFS 5672-08-2022 Molecular mechanism of splicing modulation by m6A RNA methylation in cancer	36	373 850.–
Rohrer Bley Carla , Prof. Dr. med. vet. Division of Radiation Oncology, Small Animal Department University of Zurich-Vetsuisse 8057 Zurich	KFS 5639-08-2022 FEline orAI squamous cell carcinoma to model human Head&Neck tumours: a phase II/III randomized trial assessing early toxicity and anti-tumour efficacy of ultra-high dose rate (FLASH) vs. conventional dose rate proton THERapy (FEATHER)	48	371 150.–
Rottenberg Sven , Prof. Department for Infectious Diseases and Pathobiology University of Bern 3012 Bern	KFS 5519-02-2022 Targeting platinum drug resistance	48	374 500.–
Rüegg Curzio , Prof. Dr med. Department of Oncology, Microbiology and Immunology University of Fribourg 1700 Fribourg	KFS 5497-02-2022 Unravelling mechanisms and therapeutic targets of obesity mediated breast cancer metastasis	30	296 900.–
Santoro Raffaella , Prof. Dr. Molecular Mechanisms of Disease University of Zurich (UZH) 8057 Zurich	KFS 5488-02-2022 Integrative genomic and proteomic analyses to dissect nucleolus functions in aggressive prostate cancer	36	375 000.–
Stacko Peter , Dr. Institut für Chemie Universität Zürich (UZH) 8057 Zürich	KFS 5658-08-2022 Controlling pharmacokinetics of cancer chemotherapy with near-infrared light	24	179 400.–
Thalmann George N. , Prof. Universitätsklinik für Urologie Inselspital Bern 3010 Bern	KFS 5510-02-2022 Identifying regulators of the crosstalk of two key signalling pathways in advanced prostate cancer	36	369 100.–
van Leeuwen Jolanda , Dr Center for Integrative Genomics Université de Lausanne (UNIL) 1015 Lausanne	KFS 5648-08-2022 Mapping the genetic networks underlying resistance to chemotherapeutics	36	374 850.–

Klinische Forschung / Recherche clinique			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Aceto Nicola , Prof. Dr. Department of Biology ETH Zurich 8093 Zurich	KFS 5636-08-2022 Circulating tumour cell clusters in pancreatic ductal adenocarcinoma	36	375 000.–
Albertini Francesca , PhD Center for Proton Therapy Paul Scherrer Institut (PSI) 5232 Villigen	KFS 5660-08-2022 Towards the clinical implementation of online daily adaptive proton therapy for patients treated in the head and neck region (H&N)	36	375 000.–
Arber-Barth Caroline , Prof. Dr. med. Oncologie Centre hospitalier universitaire vaudois (CHUV) 1066 Epalinges	KFS 5686-08-2022 Rejection resistant allogeneic chimeric antigen receptor T-cells for acute leukaemia	36	361 750.–
Bassani-Sternberg Michal , Dr Oncology Centre hospitalier universitaire vaudois (CHUV) 1066 Epalinges	KFS 5637-08-2022 Antigen discovery in tumours post immune checkpoint blockade therapy for development of novel neoantigen-enriched TILs-ACT	36	361 300.–
Beck Popovic Maja , Prof. Département Femme-Mère- Enfant Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS 5523-02-2022 High-risk neuroblastoma Study 2 (HR2-NBL) of SIOP-Europe-Neuroblastoma (SIOPEN)	48	244 650.–
Boss Andreas , Prof. Dr. Dr. Institut für diagnostische und interventionelle Radiologie UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS 5524-02-2022 Artificial intelligence for the detection of cancer in spiral breast-CT	36	354 450.–
Coukos George , Prof. Department of Oncology Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS 5541-02-2022 Pilot study to assess the feasibility, safety and efficacy of adoptive transfer of autologous tumour-infiltrating lymphocytes enriched for tumour antigen specificity (NeoTIL) in patients with hypermutated gastrointestinal tumours	36	374 500.–
Depeursinge Adrien , Prof. Dr. Institute of Information Systems University of Applied Sciences and Arts Western Switzerland Valais (HES-SO Valais-Wallis) 3960 Sierre	KFS 5549-02-2022 The value of modern multimodal imaging augmented with ARTificial intelliGence for the management of brain mEtastases Treated with stereotactic radiosurgery (TARGET)	36	353 200.–

Dummer Reinhard , Prof. Dermatologische Klinik UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS 5525-02-2022 Predictive bio-markers in BCC patients treated with Hedgehog inhibitors and anti-PD1	36	371 150.–
Fankhauser Christian , PD Dr. med. Klinik für Urologie Luzerner Kantonsspital 6000 Luzern	KFS 5489-02-2022 Implementation of microRNA-371 into the follow-up protocol of men with localised testicular germ cell tumours (microRNA-TARGET)	48	369 750.–
Hegi Monika , Prof. Dr Department of Clinical Neurosciences Centre hospitalier universitaire vaudois (CHUV) 1066 Epalinges	KFS 5555-02-2022 Molecular prediction of the natural clinical course of IDHmt low grade glioma to guide treatment decisions	24	250 000.–
Heim Markus Hermann , Prof. Gastroenterologie/Hepatology Clarunis – Universitäres Bauchzentrum Basel 4031 Basel	KFS 5486-02-2022 Testing hepatocellular cancer organoids with drugs to identify vulnerabilities and novel combinations	36	374 000.–
Hötker Andreas , PD Dr. med. Institut für diagnostische und interventionelle Radiologie UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS 5613-08-2022 Tumour heterogeneity of clear cell renal cell carcinoma assessed by multiparametric MRI with direct radiological-histopathological correlation	36	147 500.–
Joerger Markus , Prof. Dr. med. et rer nat. Departement Onkologie/Hämatologie Kantonsspital St. Gallen (KSSG) 9007 St. Gallen	KFS 5700-08-2022 Identifying new therapeutic approaches targeting ErbB receptor family for melanoma patients with resistance to immunotherapy – a major unmet need	36	363 600.–
Kappos Elisabeth Artemis , PD Dr. med. Department of Plastic, Reconstructive, Aesthetic and Hand Surgery University Hospital Basel 4055 Basel	KFS-5590-01-2022 Surgical versus conservative complex physical decongestion therapy (CDT) for chronic breast cancer-related lymphedema (BCRL): A pragmatic, randomized, multicentre superiority trial	60	399 862.–
Largiadèr Carlo R. , Prof. Dr. phil. nat. Universitätsinstitut für Klinische Chemie Inselspital Bern 3010 Bern	KFS 5668-08-2022 A new method for enabling a precision medicine approach to 5-fluorouracil therapy	18	140 200.–
Mortezavi Ashkan , PD Dr. med. Urologie Universitätsspital Basel 4031 Basel	KFS 5552-02-2022 An organoid-based co-clinical pilot trial in metastatic prostate cancer	36	241 000.–

<p>Rizzo Stefania Maria Rita, PD Dr med. Istituto Imaging della Svizzera Italiana Ente Ospedaliero Cantonale (EOC) 6900 Lugano</p>	<p>KFS 5521-02-2022 Quantitative assessment of sarcopenia, osteopenia and fat distribution in patients with castration resistant prostate cancer before and during therapy with enzalutamide, a novel endocrine agent</p>	36	246 600.–
<p>Sadowski Martin, Dr. Institute of Pathology University of Bern 3008 Bern</p>	<p>KFS 5539-02-2022 Targeting drug-tolerant persister cells - an early offensive against acquired drug resistance in pancreatic neuroendocrine tumours</p>	36	358 900.–
<p>Stieb Sonja, Dr. med. Radio-Onkologie-Zentrum Kantonsspital Aarau AG 5001 Aarau</p>	<p>KFS 5681-08-2022 Therapy-associated saliva and taste change evaluation (TASTE) in head and neck cancer patients undergoing radiotherapy; a multicentre study</p>	36	241 600.–
<p>Unkelbach Jan, Prof. Dr. Klinik für Radio-Onkologie UniversitätsSpital Zürich (USZ) 8091 Zürich</p>	<p>KFS 5645-08-2022 Towards personalized elective nodal irradiation of head&neck squamous cell carcinoma</p>	42	357 200.–
<p>Usemann Jakob, PD Dr. med., Dr. phil. nat. Pediatric Pulmonolgy University Hospital Zurich (USZ) 8032 Zurich</p>	<p>KFS 5511-02-2022 Novel lung function testing and lung imaging to identify origins of pulmonary dysfunction in childhood cancer patients</p>	36	366 400.–
<p>Velin Dominique, Dr Service de gastro-entérologie et d'hépatologie Centre hospitalier universitaire vaudois (CHUV) 1066 Epalinges</p>	<p>KFS 5631-08-2022 Development of adjuvant therapies to increase cancer immunotherapies efficacy of H. pylori infected patients</p>	36	352 700.–
<p>Zwahlen Daniel Rudolf, Prof. Dr. med. Institute for Radiation Oncology Kantonsspital Winterthur 8401 Winterthur</p>	<p>KFS 5535-02-2022 Stereotactic multiple fraction radiotherapy for non-spine bone metastases</p>	48	153 600.–

Epidemiologische Forschung / Recherche épidémiologie			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Schneider Cornelia, Dr. Spitalpharmazie Universitätsspital Basel 4031 Basel	KFS 5682-08-2022 Comparing several pancreatic cancer risk scores or models in regard to the diagnostic performance and availability of necessary parameters in primary care records of a cohort of patients with recently diagnosed diabetes mellitus	24	24 750.–

Psychosoziale Forschung / Recherche psychosociale			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Everts Regula, Prof. Dr. Children's University Hospital Inselspital Bern 3010 Bern	KFS 5515-02-2022 Training the body and the brain of children with cancer using an e-health tool	36	307 100.–
Berna Renella Chantal, Prof. Anesthesiology University of Lausanne 1011 Lausanne	KFS 5667-08-2022 HypnERAS- a study of acute integrative oncology: randomized controlled trial of a brief postoperative hypnosis intervention after major abdominal surgery in the enhanced recovery after surgery protocol	12	120 400.–

Health Services Research			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Colomer Lahiguera Sara, Dr Department of Oncology - Lausanne Hospital (CHUV) Institute of Higher Education and Research in Health Care (IUFERS) 1010 Lausanne	KFS 5649-08-2022 Patient, caregiver, and healthcare professional experience in adoptive cell therapies: an experience-based co-design study	24	221 850.–

Stipendien 2022

Bourses 2022

Unterstützt von: / Soutenus par:

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

Gesuchsteller/In	Projektnummer Projekttitle	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Bergsma Patrick , Dr. med. Department of Otolaryngology, Head and Neck Surgery Kantonsspital St. Gallen (KSSG) 9016 St. Gallen	KFS BIL 5516-02-2022 The interplay between the genomic and transcriptomic landscape and drug sensitivity of oral squamous cell carcinoma in young patients Destination: Garvan Institute of Medical Research, Sydney, AUS	24	124 000.–
Epiney Justine , Mrs ISREC-SV Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	MD-PhD 5595-06-2022 SAMW MD-PhD Stipendium / Identification of resistance mechanisms limiting antibody-dependent cellular phagocytosis (ADCP) in B-cell lymphoma	36	191 553.–
Kaymak Deniz , Mr. Department of Biomedicine University Hospital Basel 4031 Basel	MD-PhD 5594-06-2022 SAMW MD-PhD Stipendium / Deciphering the role of ID1 in tumor-associated microglia in glioblastoma	36	188 250.–
Kim James , Mr. Department Pediatric Oncology University Children's Hospital Zurich 8032 Zurich	MD-PhD 5596-06-2022 SAMW MD-PhD Stipendium / Relapsed TCF3-PBX1 ALL - identifying drivers of resistance in a model of relapsed very high risk ALL	24	126 601.–

Tozzi Alessandra , Dr. med. Gynecology and Obstetrics Basel University Hospital 4057 Basel	KFS BIL 5550-02-2022 Glycoproteomic characterization of lipoprotein (a) as a novel biomarker for early detection of ovarian cancer Destination: Institute for Glycomics, Gold Coast campus, Griffith University, Queensland, AUS	24	124 000.–
--	--	----	-----------

Im [Forschungsportal](#) finden Sie Informationen zu allen Projekten, die die Stiftung Krebsforschung Schweiz und ihre Partnerorganisation Krebsliga Schweiz seit dem Jahr 2005 gefördert haben.

Dans le [portail de recherche](#), vous trouverez les informations sur tous les projets soutenus par la fondation Recherche suisse contre le cancer et son organisation partenaire, la Ligue suisse contre le cancer, depuis 2005.